Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


July 06, 2015 11:38 PM ET

Pharmaceuticals

Company Overview of Millennium Pharmaceuticals, Inc.

Company Overview

Millennium Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes oncology investigational compounds for the treatment of cancer worldwide. It offers VELCADE for injection, a cancer therapy for the treatment of patients with multiple myeloma and relapsed mantle cell lymphoma; ADCETRIS, an antibody drug conjugate for post-transplant and frontline Hodgkin lymphoma, cutaneous T-cell lymphoma, and mature T-cell lymphoma; LEUPLIN, a therapy for prostate cancer, breast cancer, and new formulation; and ORTERONEL, a lyase inhibitor for metastatic castration resistant prostate cancer. The company’s development pipeline also includes IXAZOMIB, a medicine for relapsed/refractor...

40 Landsdowne Street

Cambridge, MA 02139

United States

Founded in 1993

966 Employees

Phone:

617-679-7000

Fax:

617-374-7788

Key Executives for Millennium Pharmaceuticals, Inc.

President of Global Oncology Business Unit
Age: 53
Head of Drug Discovery Unit
Head of Oncology Therapeutic Area Unit
Chief Counsel and Chief Compliance Officer
Site Head of Corporate Communications
Compensation as of Fiscal Year 2015.

Millennium Pharmaceuticals, Inc. Key Developments

Takeda and ImmunoGen Partner to Develop Anti-Cancer Therapeutics

Takeda Pharmaceutical Company, through its wholly owned subsidiary Millennium Pharmaceuticals, has signed an agreement with ImmunoGen to develop and commercialise anti-cancer therapeutics up to two undisclosed targets. As part of the deal, Takeda has secured exclusive rights to use ImmunoGen's antibody-drug conjugate (ADC) technology, including its new DNA-acting IGN payload agents to develop targeted anti-cancer therapeutics. Takeda oncology drug discovery unit head Dr. Christopher Claiborne said: "ADC technology is a critically important tool in addressing unmet needs in oncology. Under the deal, ImmunoGen will receive $20 million upfront payment and is also eligible to receive milestone payments up to $210 million for each target, in addition to royalties on the commercial net sales of any resulting ADC products. Takeda will take responsibility for the development, manufacturing and marketing of any ADC products resulting from the deal. The deal will also allow Takeda to have a licence for a third target for an additional upfront fee.

Millennium, Subsystem Technologies Inc, WisEngineering LLC and International Logistics Systems, Inc. Win $29,967,029 Federal Contract

Millennium was awarded a share of a $29,967,029 federal contract by the U.S. Army Contracting Command, Picatinny Arsenal, New Jersey, for weapon system and munitions life cycle supportability services in support of the Army Research Development and Engineering Command. Subsystem Technologies Inc.; WisEngineering LLC; and International Logistics Systems, Inc. shared in the award amount.

Harris & Harris Group, Inc. Enters into Collaboration Agreement with Millennium Pharmaceuticals, Inc. to Develop Next-Generation Fleximer(R) Antibody-Drug Conjugates

Harris & Harris Group, Inc. announced that it has entered into a collaboration agreement with Millennium Pharmaceuticals, Inc. to develop next-generation Fleximer(R) antibody-drug conjugates (ADCs). Mersana's proprietary conjugation technology is comprised of the company's biodegradable Fleximer polymer and a broad array of customizable linker chemistries matched to Mersana's diverse, cytotoxic payloads. Under the agreement, Takeda will provide an upfront payment to Mersana for the right to utilize Fleximer technology to develop novel ADC candidates. Mersana is responsible for conducting research and creating ADCs that are conjugates of Takeda's antibodies and Mersana's diverse payload platforms, which combine a cytotoxic payload with the Fleximer polymer and custom linkers. In addition to providing antibodies, Takeda is responsible for product development, manufacturing and commercialization of any Fleximer-ADC products. Mersana, in addition to an upfront payment, is eligible to receive milestones and royalties on worldwide net sales of any resulting ADC products.

Similar Private Companies By Industry

Company Name Region
Scandinavian BioPharma AS United States
Arkansas Research Medical Testing, LLC United States
Prostagen, Inc. United States
G1 Therapeutics, Inc. United States
Airmid Incorporated United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Millennium Pharmaceuticals, Inc., please visit www.millennium.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.